#Lunit #Wellington #Volpara Health #New Zealand #ECR 2025

Volpara Health's Leadership and Innovation in Breast Health

Volpara Health, a recognized leader in AI-driven breast health solutions, has announced significant transitions and milestones. As of April 1, 2025, Craig Hadfield will take over as CEO, succeeding Teri Thomas, who has guided the company since its transformation began in 2022. Under Thomas's leadership, Volpara Health experienced substantial growth, increasing its annual recurring revenue to over $34 million and positioning itself for future advancements.

Craig Hadfield steps into the CEO role with a strong background in the company’s financial and operational strategies. Expressing his commitment, he stated, "I'm honored to lead Volpara into its next phase of innovation and impact," emphasizing his eagerness to enhance breast health and improve care for patients through advanced technology.

Integration with BOADICEA Risk Model

In addition to leadership changes, Volpara Health has achieved an important integration milestone by establishing its volumetric breast density assessment as a validated input within the BOADICEA breast cancer risk model. This integration enhances the accuracy of breast cancer risk assessments, utilizing the latest enhancements in the BOADICEA software version and aligning with the widely recognized NCCN guidelines.

The inclusion of Volpara density data allows healthcare providers to utilize current patient information seamlessly and improves decision-making regarding additional imaging and interventions. Health professionals in multiple regions, including Australia, the EU, the UK, and Canada, have access to this evidence-based tool, enabling a more personalized approach to breast cancer risk management.

Record High Research Presentation at ECR 2025

Furthermore, Volpara and its partner Lunit marked a historic achievement by presenting a record number of 21 independent research abstracts at the European Congress of Radiology (ECR) 2025. This remarkable participation showcases the increasing relevance of AI technology in breast health within the global radiological community. The company’s commitment to innovation and research is reflected in its collaborative efforts, paving the way for advancements in cancer detection and patient care.

As Volpara Health takes these important steps under new leadership, it remains steadfast in its mission to save families from cancer. The integration of sophisticated AI tools into established healthcare practices aims to enhance the ability of providers to assess and manage risks associated with breast cancer effectively.

About Volpara Health

Headquartered in Wellington, New Zealand, Volpara Health has transformed the landscape of breast health management. Its AI-driven software solutions are currently used in over 3,500 facilities and impact nearly 18 million patients annually. The software is designed not only to assess breast density but also to streamline operations, aid in compliance, and improve overall patient care. As the company continues its journey of innovation and expansion, it solidifies its reputation as a trusted partner among leading global healthcare institutions.

For more information on Volpara’s initiatives and services, visit www.volparahealth.com.